Doxorubicin-loaded silk films: Drug-silk interactions and in vivo performance in human orthotopic breast cancer

Biomaterials

Volumn 33, Issue 33, 2012, Pages 8442-8450

  Seib, F Philipp ^a   Kaplan, David L ^a  

^a Tufts University   (United States)

Author keywords

Adriamycin; Antitumour; Cancer; Doxorubicin; Silk

Indexed keywords

ADRIAMYCIN; AFFINITY BINDING; ANTITUMOUR; BREAST CANCER; BREAST CANCER MODELS; CANCER; CRYSTALLINITIES; DOXORUBICIN; EQUIVALENT DOSE; IN-VIVO; LOCOREGIONAL CONTROL; MALIGNANT DISEASE; ORTHOTOPIC; PROLONGED RELEASE; RELEASE RATE; SILK FILM; THERAPEUTIC IMPACT; TUMOUR GROWTH;

ADSORPTION; CHEMOTHERAPY; DISEASE CONTROL; DISEASES; TUMORS;

SILK;

DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER LOCALIZATION; CARDIOTOXICITY; DRUG ADSORPTION; DRUG CYTOTOXICITY; DRUG FORMULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MEMBRANES, ARTIFICIAL; MICE; SILK;

MUS;

EID: 84866175348     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.004     Document Type: Article

References (46)

1. Tobias J., Hochhauser D. Cancer and its management 2010, Wiley-Blackwell, Oxford, UK. 6 ed.
2. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002, 347:1233-1241.
3. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347:1227-1232.
4. Komoike Y., Akiyama F., Iino Y., Ikeda T., Tanaka-Akashi S., Ohsumi S., et al. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer 2005, 12:104-111.
5. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995, 345:1008-1012.
6. Westphal M., Ram Z., Riddle V., Hilt D., Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir 2006, 148:269-275. discussion 275.
7. Tauro J.R., Gemeinhart R.A. Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrixes. Bioconjug Chem 2005, 16:1133-1139.
8. Guo D.D., Hong S.H., Jiang H.L., Kim J.H., Minai-Tehrani A., Kim J.E., et al. Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer. Biomaterials 2012, 33:2272-2281.
9. Guo D.D., Xu C.X., Quan J.S., Song C.K., Jin H., Kim D.D., et al. Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Biomaterials 2009, 30:4777-4785.
10. Le Renard P.E., Jordan O., Faes A., Petri-Fink A., Hofmann H., Rufenacht D., et al. The in vivo performance of magnetic particle-loaded injectable, in situ gelling, carriers for the delivery of local hyperthermia. Biomaterials 2010, 31:691-705.
11. Han H.D., Mora E.M., Roh J.W., Nishimura M., Lee S.J., Stone R.L., et al. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther 2011, 11:839-845.
12. St'astny M., Plocova D., Etrych T., Kovar M., Ulbrich K., Rihova B. HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy. J Control Release 2002, 81:101-111.
13. Ta H.T., Dass C.R., Dunstan D.E. Injectable chitosan hydrogels for localised cancer therapy. J Control Release 2008, 126:205-216.
14. Panilaitis B., Altman G.H., Chen J., Jin H.J., Karageorgiou V., Kaplan D.L. Macrophage responses to silk. Biomaterials 2003, 24:3079-3085.
15. Meinel L., Hofmann S., Karageorgiou V., Kirker-Head C., McCool J., Gronowicz G., et al. The inflammatory responses to silk films in vitro and in vivo. Biomaterials 2005, 26:147-155.
16. Ma X., Cao C., Zhu H. The biocompatibility of silk fibroin films containing sulfonated silk fibroin. J Biomed Mater Res B Appl Biomater 2006, 78:89-96.
17. Omenetto F.G., Kaplan D.L. New opportunities for an ancient material. Science 2010, 329:528-531.
18. Vepari C., Kaplan D.L. Silk as a biomaterial. Prog Polym Sci 2007, 32:991-1007.
19. Rockwood D.N., Preda R.C., Yucel T., Wang X., Lovett M.L., Kaplan D.L. Materials fabrication from Bombyx mori silk fibroin. Nat Protoc 2011, 6:1612-1631.
20. Hofmann S., Foo C.T., Rossetti F., Textor M., Vunjak-Novakovic G., Kaplan D.L., et al. Silk fibroin as an organic polymer for controlled drug delivery. J Control Release 2006, 111:219-227.
21. Lu Q., Wang X., Hu X., Cebe P., Omenetto F., Kaplan D.L. Stabilization and release of enzymes from silk films. Macromol Biosci 2010, 10:359-368.
22. Hines D.J., Kaplan D.L. Mechanisms of controlled release from silk fibroin films. Biomacromolecules 2011, 12:804-812.
23. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin Oncol 1992, 19:670-686.
24. Seib F.P., Maitz M.F., Hu X., Werner C., Kaplan D.L. Impact of processing parameters on the haemocompatibility of Bombyx mori silk films. Biomaterials 2012, 33:1017-1023.
25. Hu X., Shmelev K., Sun L., Gil E.S., Park S.H., Cebe P., et al. Regulation of silk material structure by temperature-controlled water vapor annealing. Biomacromolecules 2011, 12:1686-1696.
26. Goldstein R.H., Reagan M.R., Anderson K., Kaplan D.L., Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 2010, 70:10044-10050.
27. Bertinchant J.P., Polge A., Juan J.M., Oliva-Lauraire M.C., Giuliani I., Marty-Double C., et al. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta 2003, 329:39-51.
28. Doroshow J.H., Locker G.Y., Ifrim I., Myers C.E. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 1981, 68:1053-1064.
29. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
30. Overgaard M., Hansen P.S., Overgaard J., Rose C., Andersson M., Bach F., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish breast cancer cooperative group 82b trial. N Engl J Med 1997, 337:949-955.
31. Harris J., Morrow M. Local management of invasive breast cancer. Diseases of the breast 1996, 487-547. Lippincott-Raven, Philadelphia, USA. J. Harris, M. Lippman, M. Morrow, S. Hellman (Eds.).
32. Tajima N., Takai M., Ishihara K. Significance of antibody orientation unraveled: well-oriented antibodies recorded high binding affinity. Anal Chem 2011, 83:1969-1976.
33. Jin H.J., Kaplan D.L. Mechanism of silk processing in insects and spiders. Nature 2003, 424:1057-1061.
34. Aoyama T., Horioka M., Nagamitsu S. Macromolecular complexes of drugs. I. Doxorubicin-heparin complex. Chem Pharm Bull 1987, 35:808-813.
35. Al-Abd A.M., Hong K.Y., Song S.C., Kuh H.J. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 2010, 142:101-107.
36. Dadsetan M., Liu Z., Pumberger M., Giraldo C.V., Ruesink T., Lu L., et al. A stimuli-responsive hydrogel for doxorubicin delivery. Biomaterials 2010, 31:8051-8062.
37. Chang G., Ci T., Yu L., Ding J. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel. J Control Release 2011, 156:21-27.
38. Zhao L., Zhu L., Liu F., Liu C., Shan D., Wang Q., et al. pH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel. Int J Pharm 2011, 410:83-91.
39. Cai S., Xie Y., Bagby T.R., Cohen M.S., Forrest M.L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 2008, 147:247-252.
40. Cai S., Thati S., Bagby T.R., Diab H.M., Davies N.M., Cohen M.S., et al. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J Control Release 2010, 146:212-218.
41. Cohen S.M., Mukerji R., Cai S., Damjanov I., Forrest M.L., Cohen M.S. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am J Surg 2011, 202:646-652. discussion 652-643.
42. Nakasone E.S., Askautrud H.A., Kees T., Park J.H., Plaks V., Ewald A.J., et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012, 21:488-503.
43. Eckhardt B.L., Francis P.A., Parker B.S., Anderson R.L. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012, 11:479-497.
44. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996, 125:47-58.
45. Jiang B., Zhang L., Wang Y., Li M., Wu W., Guan S., et al. Tanshinone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin in vitro and in vivo. Food Chem Toxicol 2009, 47:1538-1544.
46. Zhu J., Zhang J., Zhang L., Du R., Xiang D., Wu M., et al. Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomed Pharmacother 2011, 65:481-485.